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Abstract 
The duocarmycins are potent antitumour agents with potential in the development of 
antibody drug conjugates (ADCs) as well as being clinical candidates in their own right. 
In this paper, we describe the synthesis of a duocarmycin monomer (DSA) that is 
suitably protected for utilisation in solid phase synthesis. The synthesis was performed 
on a large scale and the resulting racemic protected Fmoc-DSA subunit was separated 
by supercritical fluid chromatography (SFC) into the single enantiomers. Application 
to solid phase synthesis methodology gave a series of monomeric and extended 
duocarmycin analogues with amino acid substituents. The DNA sequence selectivity 
was similar to previous reports for both the monomeric and extended compounds. 
The substitution at the C-terminus of the duocarmycin caused a decrease in 
antiproliferative activity for all of the compounds studied. An extended compound 
containing an alanine at the C-terminus was converted to the primary amide or to an 
extended structure containing a terminal tertiary amine but this had no beneficial 
effects on biological activity.    
 
 
Introduction 
The duocarmycin family of natural products incorporates the parent molecule 
duocarmycin SA (1, Figure 1),1 several naturally occurring analogues2 and the 
extended and sandwiched compounds CC-10653 (2) and yatakemycin (3).4 The mode 
of action of these compounds, involving reversible alkylation of the N3 of adenine 
through shape dependant activation on binding to the minor groove of DNA, has been 
the subject of extensive investigation5 and has led to the design and synthesis of 
numerous analogues.6-12 Most recently, research has focussed on prodrugs that are 
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reductively13,14 or oxidatively-activated15,16 (4-6) or that carry glycosidic linkages.17,18 
This desire to generate prodrug structures is due to the ultrapotent activity of the drug 
molecules, which significantly narrows the therapeutic window for this class of 
compound as alkylation and subsequent anti-proliferative effects occur in all dividing 
cells, as with classical antitumour cytotoxics.  
  
Figure 1. Duocarmycin SA, and biooxidative and bioreductive prodrugs 
One route into the design of new molecular entities with therapeutic potential whilst 
minimising cytotoxicity is via tumour cell targeting, rather than prodrug design. 
Antibody-drug conjugates, in which the antibody targets a highly cytotoxic molecule 
to the tumour site of action, have met with recent success in the clinic.19 The enediyne 
antibiotic calicheamicin was conjugated to an anti-CD33 antibody to generate the 
clinically utilised agent gemtuzumab ozogamicin for the treatment of acute 
myelogenous leukemia (AML).20 Although this was subsequently withdrawn due to 
toxicity problems, it paved the way for brentuximab vedotin21 and trastuzumab 
emtansine,22 which are used in the treatment of Hodgkins lymphoma and breast 
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cancer, respectively. Key to the design of antibody drug conjugates is the linker 
between the cytotoxic drug and the antibody. In gemtuzumab ozogamicin, the linker 
was cleaved under the acidic conditions that are formed in the endosomal 
compartment when the antibody is internalised in the cell.[11] Brentuximab vedotin 
utilises a cathepsin cleavable linker to the antimitotic agent monomethylauristatin E.23 
Trastuzumab emtansine contains a non-cleavable linker, such that as the protein is 
degraded in the environment of the endosome, the small molecule is released with 
the linker and a lysine residue still attached, nevertheless still exerting a cytotoxic 
effect.24 
These latter two approaches require the attachment of the potent drug molecule 
through a peptidic linker. The ability to prepare multiple analogues via solid phase 
peptide chemistry is thus particularly attractive for ADC design. The duocarmycin SA 
alkylation subunit (termed (+)-DSA) is an amino acid ester and so is ideally placed to 
be incorporated into peptide synthesis. To our knowledge, there have been no 
descriptions to date of the incorporation of (+)-DSA directly into solid phase peptide 
methodology and we describe here the synthesis of a monomer 7 that is suitably 
protected for Fmoc-based solid phase synthesis. We also describe preliminary studies 
of the incorporation of the subunit onto the solid phase with a peptide moiety at the 
C-terminus for both a simple alkylating agent (8-13) and an extended DSA analogue 
(14-18). The effects of the presence of the differing side chains on DNA binding and 
biological activity are shown. Particularly striking was the discovery that substitutions 
at this position have a profound effect on the antiproliferative activity of the 
compounds. Hydrolysis of the simple ester 30 to give the free acid 31 completely 
eliminates the activity whereas the presence of a free amino acid demonstrates 
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considerable variability. The combination of a free amino acid with an extended group 
on the N-terminus increases the antiproliferative activity but incorporation of a 
terminal amine or amide has little effect on activity. 
  
Figure 2. Compounds 7-18 made in this study. 
Results and Discussion 
Synthesis of the monomer for Fmoc-chemistry 
Several synthetic routes to the (+)-DSA subunit have been described,25-28 but key to 
success in this project was the scalability, so that large amounts of a protected form 
were available for application to the solid phase. There are also a smaller number of 
stereoselective routes to the target compound and analogs,4d, 28 but in this instance, 
it was felt a late stage separation of the enantiomers, on a large scale, would be useful 
as it was felt that the seco form of DSA  that would be generated from the planned 
racemic route would serve as a suitable solid phase building block. This is because the 
halide leaving group allows in vivo spiro-cyclisation, thus providing compounds of 
biological interest in fewer synthetic steps post cleavage. Our synthesis began with 50 
g of commercially available 2-hydroxy-4-nitroaniline 19 which was protected as the 
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benzyl ether 20 in two batches (BnBr, K2CO3, DMF, RT, 99%, Scheme 1) and then 
regioselectively iodinated, again in two batches, using N-iodosuccinimide (NIS) and 
catalytic acid to give over 100 g of the iodo compound 21 in 92% yield overall. This set 
the stage for investigation of cross-coupling reactions to introduce an alkyne substrate 
and potentially to induce cyclisation to the indole in one pot as described previously.29 
The Negishi coupling worked smoothly (methyl propiolate, Pd(PPh3)2Cl2, ZnBr2, N,N-
Diisopropylethylamine (DIPEA), DMF, 66 °C, 77%)  but we had elected on the large 
scale not to use the dimesylation/mesylation approach29 as it increased the number 
of manipulations required. As such, in spite of several attempts under differing 
conditions, we could not induce the cyclization of 22 to occur. As a consequence, the 
coupling was followed by cyclisation using tetrabutylammonium fluoride,30 which 
generated the indole 23 and this was immediately protected as the N1-Boc compound 
24 (Boc2O, 4-dimethylaminopyridine (DMAP), CH2Cl2). The two steps were conducted 
on a 60 g (184 mmol) scale and gave a modest 39% yield of the pure protected indole 
24 after purification by flash column chromatography. We also investigated a 
Sonogashira route to the same indole, which gave similar yields on a small scale but 
could not be scaled up due to problems associated with the purification.  The rest of 
the synthesis to the di-Boc protected indole followed published methodology31 and 
utilized the 5-exo-trig free radical cyclisation reaction32,33 to introduce the 
dihydropyrrole ring structure. Hydrolysis of the ester 28 was followed by Boc-removal 
under acidic conditions to generate a substrate that was regioselectively Fmoc 
protected with Fmoc-Cl to give the substrate for peptide synthesis. The final yield for 
the full synthesis was 3% over 13 steps and generated over 8 g of the Fmoc protected 
monomer 7 as a racemic mixture. 
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Scheme 1. i: BnBr, K2CO3, DMF, 98.5% (mean 2 batches). ii: NIS, H2SO4, DMF, 92% (mean 2 batches). iii:  ZnBr2, 
Pd(PPh3)2Cl2, DIPEA, Methyl propiolate, DMF, 66 °C, N2, 77%. iv: TBAF, THF, 66 °C. v: Boc2O, DMAP, CH2Cl2, 39% (2 
steps). vi: Zn, NH4Cl, Boc2O, DMAP, THF:Water. vii: NIS, H2SO4, DMF, 59% (3 steps). viii: Potassium tert-butoxide, 
1,3-dichloropropene, DMF, 62%. ix: AIBN, Tris(trimethylsilyl)silane (TTMSS), Toluene, 90 °C, N2, 70% x: LiOH, 
THF:MeOH:Water, 100%. xi: 4M HCl in Dioxane. xii: Fmoc-Cl, NaHCO3, THF:Water, 80% (2 Steps).  
Separation of enantiomers using supercritical fluid chromatography. 
The application of supercritical fluid chromatography for the chiral resolution of 
racemic mixtures is well established.34,35 Supercritical fluids combine the density, and 
dissolution character of a liquid, with a viscosity, and diffusion behaviour more 
comparable to a gas. The low viscosity improves mass-transfer kinetics, and permits 
the use of fast flow rates with high acuity columns. These properties make them ideal 
mobile phases, and allow for highly efficient separations. As such this technique is 
particularly attractive for preparative scale work, and was employed here for the 
isolation of each enantiomer of 7. 
Separation was affected using a Chiralpak AD-H column (250 x 30 mm, 5 micron), and 
an isocratic flow of 50% CO2, and 50% IPA containing 0.1% TFA, at 45 mL per min. The 
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back pressure was regulated at 10 MPa, and column temperature controlled at 40 oC. 
A racemate of 7 (9.8 g) was dissolved in THF:MeOH 1:1 (100 mL), and 1.25 mL (125 
mg) injected every 9 min. Fractions were monitored by UV (220 nm), collected, 
combined and dried to afford 2.82 g of peak 1 (5.5 min), and 3.1 g of peak 2 (7 min), 
both as cream solids (α = 1.27).   
Analytical supercritical fluid chromatography of peak 1, showed a 7% impurity with 
similar retention time to peak 2. The mass of this peak suggested the loss of Cl as 
opposed to racemisation. NMR analysis showed no evidence of this impurity, with the 
1H NMR of both enantiomers being identical to that of the racemate, with the 
exception of a small amount of residue IPA. We propose that the observed impurity 
may be an artefact of supercritical fluid chromatography, and represent a transient 
alternative spirocyclisation through the indole nitrogen,36 perhaps promoted by the 
pressure and acidic buffer.      
Peak 1 was assigned as the natural enantiomer based on the sign of specific rotation 
matching that of the well characterised seco-Boc-DSA derivative.37 Peak 1 [α]25D –20° 
(c 0.05, DMF), Peak 2 [α]25D +20° (c 0.05, DMF). This assignment was further confirmed 
by the DNA alkylation sequence selectivity of the extended agent 14, which matches 
that found for the natural products (i.e. alkylation of an A at the 3’-end of an AT 
sequence).10   
Application of Fmoc-protected monomer to solid phase peptide synthesis. 
The suitability of 7 to serve as a building block for Fmoc-based solid phase synthesis 
was initially explored using a racemic batch of the compound accessed from a small 
scale pilot synthesis. In this preliminary study (Scheme 2), a commercially available 
Wang supported alanine resin was first prepared for coupling by swelling in CH2Cl2 for 
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30 min, followed by DMF for a further 30 min. Subsequent treatment with 40% 
piperidine in DMF for 10 min, and 20% piperidine in DMF for 5 min twice, removed 
the alanine’s Fmoc protection. A positive Kaiser Test confirmed the present of the free 
amine. The resin was then treated with a modest excess of 7 (1.1 eq. based on the 
manufacture’s resin loading) which had been pre-activated for 30 s prior to addition, 
by treatment with an equimolar quantity of N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (HBTU), and a twofold excess of both 
hydroxybenzotriazole (HOBt.H2O) and DIPEA in DMF. After two hours of shaking, the 
Kaiser test was repeated. A negative result was observed, and suggested complete 
coupling of 7 to the Wang supported alanine. The resin was treated again with 
piperidine in DMF as previously described, affecting removal of Fmoc protection from 
the indoline nitrogen. This allowed coupling of a further alanine residue, using a 
fivefold excess of Fmoc-protected alanine for 45 min, which had been preactivated for 
30 s with equimolar quantities of HBTU and HOBT.H2O, and a twofold excess of DIPEA 
in DMF. The resin was then prepared for cleavage by removal of the final Fmoc group 
and extensive washing with CH2Cl2, followed by drying under a stream of N2.  
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Scheme 2. Preliminary solid phase synthesis studies using racemic 7 
The resin was cleaved using standard conditions for peptide synthesis.38 The dried 
resin was treated with a solution of 95% TFA, 2.5% triisopropylsilane (TIPS), and 2.5% 
H2O for 2 h. The cleavage mixture was filtered and concentrated, followed by 
precipitation with the addition of cold Et2O. HPLC analysis of the crude product (Figure 
3a) revealed the formation of several significant side products. It was suspected that 
these products may have resulted from degradation during cleavage as opposed to 
representing problems during the synthesis. As a result the synthesis was repeated to 
allow optimisation of the cleavage conditions. 
The dried resin was divided into 10 mg portions, and subjected to different cleavage 
conditions. The results of the HPLC analysis of the crude products are shown in Figure 
3. Reducing the concentration of TFA to 50% in CH2Cl2 and omission of the scavengers 
(TIPS, H2O), led to a reduction in the number of side products (Figure 3b versus 3a). 
However the product peak at 9 min was still accompanied by two significant side 
products at 9.5 and 9.7 min.  Cleavage with 95% TFA and 5% CH2Cl2 in the absence of 
scavengers (Figure 3c) led to almost complete absence of the product peak with the 
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HPLC trace now being dominated by the side products at 9.5 and 9.7 min. Finally, 
reducing the concentration of TFA and including the scavengers (Figure 3d, 47.5% TFA, 
47.5% CH2Cl2, 2.5% TIPS, 2.5% H2O) produced an HPLC trace dominated by the product 
peak at 9 min. Mass spec analysis confirmed this peak to be the desired product.  
Interestingly closer inspection of the HPLC trace under the most destructive cleavage 
conditions (Figure 3c) revealed that, not only did the product peak no longer 
dominate, but there was also a large decrease in intensity compared to the other 
conditions despite the crudes having been analysed in the same volume of methanol. 
This suggested that the amount of material recovered from the resin had been 
reduced. Repeating the cleavage did not lead to recovery of more material. This led to 
the proposal that Wang resin may not be the most appropriate choice for syntheses 
incorporating 7. Indeed, Wang resin has previously been suggested to be problematic 
for peptides containing the indole side chain of tryptophan.39 The Wang linker can be 
cleaved at more than one position leading to free benzyl cations that can attack the 
nucleophilic positions of the indole. Furthermore, resin-bound cations have been 
speculated to undergo an irreversible back alkylation with the tryptophan side chain 
leading to reduced yields.40 Considering that in the indole structure of 7, it is the more 
nucleophilic 3- position that is unsubstituted in comparison to the 2-position of the 
tryptophan side chain, it may be particularly susceptible to such side reactions.  
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Figure 3: HPLC analysis of crude HO-Ala-DSA-Ala-NH2 after cleavage under 
varying conditions. a) 95% TFA, 2.5% TIPS, 2.5% H2O. b) 50% TFA, 50% CH2Cl2. 
c) 95% TFA, 5% CH2Cl2. d) 47.5% TFA, 47.5% CH2Cl2, 2.5% TIPS, 2.5% H2O. 10 
mg of dried resin was cleaved under either conditions a, b, c, or d with 5 mL 
of the respective cleavage cocktail for 2 h. The cleavage mixture was filtered 
and evaporated to dryness. The crude was dissolved in 1 mL of CH3OH and 
analysed by HPLC at 254 nm. Agilent Eclipse XDB-C18 column, 4.8 x 150 mm, 
5 µM. Solvent A: [Water and 0.05% TFA], Solvent B: [ACN and 0.05% TFA]. 
Gradient: 0% [B] to 95% [B], from 0 min to 15 min, 95% [B] to 0% [B] from 15 
to 20 min. Monitored UV 254 nM. 
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As a result of these concerns a qualitative analytical screen of available resins was 
conducted. For these tests the C-terminal alanine was replaced with lysine and the 
indoline nitrogen capped with 5 equiv. of AcCl and 10 equiv. of DIPEA in DMF for 45 
min (Scheme 3). This synthesis was carried out on the same 0.038 mM scale with 
identical reaction times, on four different resins: 2Cl-Trt resin, Rink amide resin, Wang 
resin, and Novo Syn Wang resin. All were cleaved using 47.5% TFA, 47.5% CH2Cl2, 2.5% 
TIPS, 2.5% H2O at the same volume for 2 h. The crude cleavage mixtures were filtered, 
evaporated to dryness, and dissolved in the same volume of CH3OH (1 mL) for HPLC 
analysis. The area of the product peak for each of the crudes was compared. As the 
same volume of CH3OH was used to dissolve the crudes, the area of the peak doses 
give a qualitative indication of the quantity of product recovered from each resin.  
Both Wang resins appeared to perform the worst and gave the same level of product 
as judged by peak area.  The best performing was 2-Cl-Trt resin, and Rink amide resin 
fell between the two extremes. 2-Cl-Trt resin can only be cleaved at the desired 
position, and the cation formed is more sterically hindered by the surrounding linker 
structure, making any potential back alkylation less likely. As 2-Cl-Trt resin has the 
further advantage of allowing cleavage to be effective with as little as 1% TFA, it was 
chosen as the resin of choice for further work.  
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Scheme 3. Qualitative analysis of the best resins and coupling reagents for addition of 7 to the solid phase. 
A similar test was used to compare available coupling reagents (Scheme 3). The same 
analogue was synthesised at a 0.016 mM scale on 2-Cl-Trt resin. The only variation 
being the reagents used to couple 7 to the resin-bound lysine. Again, a qualitative 
comparison of the area of the product peak on HPLC was carried out. -
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxid 
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hexafluorophosphate (HATU) appeared to be the best performing coupling reagent 
followed by HBTU, (Benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBop), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDCI), and N,N′-Diisopropylcarbodiimide (DIC). As a result, HATU was used as the 
coupling reagent for further work. 
Following these initial experiments, the natural enantiomer of 7, accessed from the 
large scale synthesis, was used to generate the library of analogues shown in Figure 2. 
Full details of their synthesis and isolated yields can be found in the experimental 
section (yields were 8 69%, 9 81%, 10, 56%, 11 48%, 12 38%, 13 19%, 14 20%, 15 16%, 
16 35%, 17 17%, 18 34% based upon resin-loading). All analogues where synthesised 
on 2-Cl-Trt resin, with the exception of 18, where Rink amide was employed to provide 
a neutral terminal amide after cleavage. When using 2-Cl-Trt resin, the cleavage 
concentration of TFA was reduced further to 1% for analogues not requiring t-butyl 
side chain deprotection, increasing to 10 or 20% and extended reaction times for 
those that did. It was found when the TFA concentration was reduced to this level, 
H2O no longer served as an effective scavenger, presumably as it was not miscible with 
the larger volumes of dichloromethane now being used. This was resolved by 
increasing the concentration of TIPS to 10%. Interestingly, if 10% H2O was also 
included, t-butyl side chain deprotection did not occur.  This might be as the 
immiscible water layer was acting as a proton sink, reducing the acidity of the CH2Cl2 
layer.  
The benzyl protecting group was removed via transfer hydrogenation using Pd-
C/HCO2NH4 on crude cleavage products, and the active compounds purified by either 
preparative reverse phase HPLC, or silica gel Flash chromatography, depending on the 
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polarity of the side chain. This reaction proceeded smoothly for all but one of the 
molecules synthesised in this study. Compound 14, containing the lysine side chain 
and the extended DNA binding structure, required careful monitoring as an alternative 
product, which had undergone dehalogenation, began to form and became the 
predominant species.  The reason for the susceptibility of 14 to this side reaction is 
unknown. It was observed that the reaction was unusually slow compared to the other 
analogues and required greater quantities of Pd-C and ammonium formate. Suspicion 
that the amine of the lysine side chain might be poisoning the catalyst, or promoting 
dehalogenation, led to attempts to perform benzyl deprotection prior to removal of 
lysine side chain protection. This was achieved by cleaving in 1% TFA to give the 
protected lysine product. However this made no difference and the side reaction was 
still encountered. The highest yield and optimum purity of the target compound was 
obtained when the reaction was carefully carried out and quenched after 1 h.       
DNA alkylation studies  
(+)-Duocarmycin SA binds to the minor groove and alkylates the N3 of adenine at the 
3’-end of an AT rich sequence, with the unnatural enantiomer displaying a similar 
sequence preference but with alkylation occurring at the 5’-end of the sequence, 
suggesting productive binding is in the other orientation, as might be expected.37 The 
alkylation subunit (+)-Boc-DSA displays a similar sequence selectivity to the unnatural 
enantiomer, essentially alkylating any A within a truncated AT sequence, down to two 
bases.41 This can be rationalised by models of both compounds in the minor groove 
that allow for productive alkylation of the same site, regardless of the binding 
orientation. It was expected that the C-terminal amino acid-linked seco-DSA 
compounds 8 – 13 would display a similar alkylation profile to the simple alkylation 
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subunit 30 (figure 4), although it was also considered that the presence of the free 
acid may affect DNA binding, so the compounds were also analysed alongside the 
hydrolysed derivative 31. 
 
 
Figure 4. Structures of 30 and 31 
Compounds 8-13 were incubated at 37 °C for 16 h with the 3’-32P-end-labeled MS1 
DNA fragment (a fragment approximately 166 base pairs in length designed to contain 
all possible tetranucleotide sequences).42 The resulting solutions were heated to 100 
°C for 3 min in order to generate cleavage1 and were then subjected to denaturing 
polyacrylamide gel electrophoresis and developed on a phosphoimager. Examples of 
the results are shown in the left hand panel of Figure 5. It is clear that the sequence 
selectivity of compounds 8-13 closely matches that for the controls 30 and 31 (which 
were analysed as the racemic mixtures) with little evidence for sequence selectivity 
other than the alkylation of an A in short AT runs, as previously suggested,41 and as 
shown in the open bars in the lower panel of Figure 5. An indication of the relative 
reactivity of the compounds towards DNA alkylation and thermal-induced cleavage is 
given by the intensity of the full length DNA band (at the top of the gel) at similar 
concentrations. The presence of significant cleavage for compound 31 suggests that 
the presence of a carboxylic acid does not affect the DNA alkylating ability of the 
subunit, as the reactivity of 31 closely matches that for 30. For most of the amino acid 
compounds, the reactivity towards DNA is decreased relative to 30 and 31, with lower 
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levels of cleavage at 5 µM concentration. The exception is the serine derivative 11, 
which maintains similar reactivity to the controls. This suggests that the presence of 
the amino acid group has a negative effect on DNA binding, though this effect is 
unlikely to be a consequence of the presence of the terminal carboxylic acid.  
The lysine functionality in 13 does not enhance the binding of the monomeric subunit, 
which was unexpected as the amino acid was incorporated so that it would enhance 
interactions with the sugar-phosphate backbone. This appears not be the case and 
might suggest that the lysine and other side chains lie along the floor of the groove on 
binding, rather than extending out into the solvent environment close to the alkylation 
site.   
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Figure 5. DNA cleavage of DNA fragment MS1 by duocarmycin derivatives. Left hand panel compounds 9-13 and 
control compounds 30 and 31. Right hand panel 14, compared with compounds 30 and 31. Tracks labelled GA are 
sequence markers for purines; control is DNA in the absence of added ligand. Ligand concentrations (µM) are 
indicated at the top of each gel lane. The lower panel shows the relative cleavage (compared with control lane) at 
each position for 14 (filled bars) and 31 (open bars) for a section of the MS1 fragment that incorporates the site of 
best cleavage for 14. The asterisk indicates the location of the best cleavage with 14. 
                     
The extended agent 14, which is more similar in structure to the full natural product 
duocarmycin SA than to the simple alkylation subunit, displayed significantly 
enhanced DNA alkylation activity compared with the other compounds (Figure 5, right 
hand panel) producing cleavage products at much lower concentrations. As expected, 
14 reacted predominantly with As at the 3’-end of AT sequences, with fewer cleavage 
sites than the other compounds. The major cleavage on this fragment is observed at 
AATTA, (asterisk in Figure 5) demonstrating a sequence selectivity that is closer to that 
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expected for the natural product. The enhancement of the alkylation seen with 14 
compared with 13 was significant with clear alkylation at 10 nM compared with 5 µM 
for the latter. 
Antiproliferative activity 
The antiproliferative activity of the compounds was measured using the human 
leukaemia cell line HL60 and an MTS assay (Table1). An initial, striking, observation 
with the control compounds 30 and 31 is the difference in biological activity. While 
racemic 30 maintains an anti-proliferative effect that is close to that seen with L1210 
mouse leukaemia cells in the literature ((+)-N-Boc-DSA, 6 nM, (-)-N-Boc-DSA, 60 nM, 
37 this study (±)-N-Ac-DSA 30, 25 nM), hydrolysis of the ester to give racemic 31 
effectively removes all antitumour effects. The DNA cleavage studies clearly showed 
that there is no difference in alkylation ability between these two compounds, 
strongly suggesting that the presence of the carboxylic acid does not affect DNA 
binding. The lack of activity is likely to derive from the free carboxylic acid, even with 
the benzoic acid-type of group in the DSA subunit, being substantially ionised at 
physiological pH and that cellular uptake with this compound is not achieved. Bearing 
in mind that the pKa of the amino acid carboxylic acid groups appended to the 
duocarmycin subunit might be expected to be lower than that of 31 and that, with the 
exception of 11, all compounds displayed a lower affinity for DNA under the alkylation 
experimental conditions, we expected the new agents to similarly lack 
antiproliferative activity. Surprisingly, this was not the case with only the Lys and β-
alanine compounds showing a complete lack of activity against HL60, although all 
compounds were between approximately 1000-10000 fold less active than 30.      
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Table 1. Antiproliferative activity of the duocarmycin compounds. Activity was assessed in HL60 human leukaemia 
cell lines and was measured using the MTS assay. For details, see the experimental section.  
It seems unlikely that there is a simple explanation for the increased activity of the 
simple amino acid derivatives. The activity of 8 and 10 may be due to increased 
hydrophobic nature of the side chains increasing passive diffusion into cells in spite of 
the presence of the free acid group or indicate a role for transport mediated uptake. 
The Ser analogue 11 may display better uptake but also benefit from its more efficient 
DNA alkylation ability once in the cell. The lysine derivative 13 will form a zwitterion 
in solution and this may explain its complete inactivity, due to the lack of cellular 
uptake, although this is then countered by the more hydrophobic extended structure 
of 14, which has reasonable activity. Compound 12, with two acid groups has low 
activity and it is unclear why the presence of the linear β-ala in 9 would lead to 
complete inactivity.      
The introduction of extended hydrophobic structure of the 5-methoxyindole 
derivatives significantly enhanced the biological activity of the compounds with the 
lysine derivative 14 now having an activity of 374 nM and the serine and alanine 
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derivatives 15 and 16 displaying a 260 and 2200 fold increase in activity, respectively. 
As the lysine derivative 14 displayed enhanced activity on binding to DNA compared 
with 30, the decreased cytotoxicity is likely to derive from what is still a limited uptake 
for these compounds, with only the alanine compound 16 having activity that 
approaches that of the simple analogue 30. In other studies, albeit in different cell 
lines, neutral duocarmycin analogues have low pM antiproliferative activity.37 
In order to further investigate the effect of the carboxylic acid and it derivatives on 
cytotoxicity, we also synthesised the N,N-dimethylamino- compound 17 and the 
neutral compound 18. Minor groove binders based upon distamycin often carry a 
positively charged end group similar to this, which enhances solubility and DNA 
binding. The inclusion of the amino-end group for 17 is to the detriment of its 
biological activity, with a 2-fold decrease in activity compared with the free acid 
compound 16, although this remains the relatively potent. Finally, the uncharged 
analogue 18 was synthesised using Rink amide resin to directly generate the amide. 
This compound was found to have similar, albeit slightly enhanced activity compared 
with the other compounds.  
Conclusions 
The duocarmycins have great potential as antitumour agents but have yet to progress 
to clinic use. Their utility in ADCs has been widely recognised, with recent disclosures 
focussed on the design of conjugates.43,44 In this paper, we show that the duocarmycin 
alkylation subunit is suitable for solid phase synthesis methods and can be added 
directly to a peptide-based linker for incorporation into a targeting construct. It would 
be possible to block the reactivity of the duocarmycin linker through phenol 
protection, either of a bioreductive, biooxidative or simple enzymatic or chemical 
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cleavage nature, but with the exquisite targeting potential of antibodies, it remains to 
be seen if this is really necessary, as the duocarmycins tend to be activated only in the 
presence of DNA.   This methodology also has potential in the design of, for example, 
covalent analogues of polyamide minor groove binders or other DNA binding 
peptides.  
The work here also clearly demonstrates that small changes in the duocarmycin 
structure, even of the extended analogues, can have profound effects on the 
antitumour activity of the compound and that this is more likely related to uptake than 
to DNA alkylation ability. Secondary amides of the C-terminus of the duocarmycin 
structure have been described that maintain their potent antitumour activity,28 
whereas in this study, we demonstrated that the presence of an OH or NH on C-
terminus, either with a carboxylic acid or a amide, leads to a decrease in activity such 
that the extended compounds only just match the antiproliferative activity of the 
truncated compound 30. That this is likely to be due to uptake is demonstrated by the 
difference in 31, where DNA alkylation ability is similar to that for 30, and for the lysine 
analogue 14, which alkylates DNA with far more efficiency than 30, but still has lower 
antitumour activity.  
Work is ongoing to explore the attachment of duocarmycins to antibodies and other 
proteins through their incorporation into peptidic linker structures and will be 
reported in due course. 
Experimental Section. 
All chemicals were reagent grade. HPLC mobile phases were prepared using HPLC 
grade solvents. THF and DMF where specified as dry were bought as such and assumed 
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to conform to the manufacturer’s standards. All water used was distilled. All DMF for 
solid phase synthesis was purchased as peptide grade. 
1H and 13C-NMR spectra were recorded in Fourier Transform mode operating at a 
nominal 1H NMR frequency of 400 MHz, using the specified deuterated solvent. The 
chemical shifts for both 1H and 13C-spectra were recorded in ppm and were referenced 
to the residual solvent peak. Multiplicities in the NMR spectra are described as: s = 
singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet, br 
= broad, appt = apparent; coupling constants are reported in Hz. High resolution mass 
spectra were obtained using a quadrupole MS. Ionisation by nano-electrospray. 
Infrared spectra were recorded as neat samples.  Thin layer chromatography was 
performed on aluminium plates coated with 0.2 mm silica gel-60 F254. After elution, 
the TLC plates were visualised under UV light. Flash chromatographic separations 
were performed on silica gel for column chromatography (particle size 60 µm).  Unless 
otherwise stated analytical RP-HPLC was performed using a C18 column, 4.6 x 150mm, 
5µM and a flow rate of 1 mL/min. Solvent A = H2O + 0.05% TFA and Solvent B = MeOH 
+ 0.05% TFA. Gradient 5% B  95% B over 15 min, 95% B  5 % B over 5 min. 
Detection wavelength 254 nm.  Unless otherwise stated preparative RP-HPLC was 
performed using a C18 column, 21.2 x 150 mm, 5 µM and a flow rate of 20 mL/min 
and a flow rate of 20 mL/min. Solvent A = 95% H2O 5% MeOH + 0.05% TFA and Solvent 
B = 95% MeOH 5% H2O + 0.05% TFA. Gradient 0 % B  100% B over 15 min, 100% B 
 0% B over 5 min. Detection wavelength 254 nm. Unless otherwise stated RP-Flash 
chromatography was performed using a pre-packed 12 g C18 column, and a flow rate 
of 20 mL/min. Solvent A = 95% H2O 5% MeOH + 0.05% TFA and Solvent B = 95% MeOH 
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5% H2O + 0.05% TFA. Gradient 0% B  100% B over 15 min, 100% B  0% B over 5 
min. Detection wavelength 254 nm. Samples were dry loaded by adsorption on Celite.  
4-Nitro-2-(phenylmethoxy)benzenamine (20)  
BnBr (21 mL, 178 mmol) was added dropwise to a stirring suspension of 2-amino-5-
nitrophenol (25 g, 162 mmol) and K2CO3 (49.3 g, 357 mmol) in DMF (250 mL) at room 
temperature. After 20 h, the reaction mixture was poured over crushed ice. The 
precipitate was collected by filtration and triturated with cold water prior to drying at 
40 OC under vacuum overnight. The reaction was repeated and the two batches 
combined to afford 78.05 g of 20 as yellow/brown amorphous solid (98.5% average 
yield over the 2 batches). Rf 0.17 (20 % EtOAc in hexane); mp 147-149 oC (Lit29 151-
153 oC). 1H NMR (CDCl3, 400 MHz) δ  7.83 ( 1H, dd,  J=2.4, 8.7),  7.77 (1H, d, J=2.4), 
7.37-7.46 (5H, m), 6.66 (1H, d, J=8.7), 5.15 (2H, s), 4.60 (2H, brs). 13C NMR (CDCl3, 100 
MHz) δ 144.6, 143.6, 138.7, 135.9, 128.9, 128.7, 128.0,  119.5, 112.1, 107.4, 71.0. IR 
(neat) νmax 3483, 3359, 3225, 3188, 3075, 2939, 2876, 1622, 1579, 1519, 1480, 1455, 
1386, 1282, 1222, 1176, 1091, 1007, 950, 914, 870, 853, 818, 797, 755, 744, 727, 697, 
643, 623 cm-1. HRMS (ES+) calculated for C13H13N2O3 (M+H)+ 245.0921 found 
245.0923. 
2-Iodo-4-nitro-6-(phenylmethoxy)benzenamine (21)  
H2SO4 (800 µL, 15.15 mmol) was added to a stirring solution of 20 (37 g, 151 mmol) in 
DMF (555 mL), followed by portionwise addition of NIS (51.1 g, 227 mmol) at room 
temperature. After 4 h, the reaction mixture was poured over crushed ice. The 
precipitate was collected by filtration and triturated with cold water, followed by cold 
hexane, prior to drying at 40 OC under vacuum overnight. The reaction was repeated 
with 39.1 g of 21 and the two batches combined to afford 105.65 g as a bright yellow 
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amorphoussolid (91.5% average yield over the 2 batches). Rf 0.31 (20 % EtOAc in 
hexene); mp 103-106 oC (Lit29 105-106 oC). 1H NMR (CDCl3, 400 MHz) δ 8.29 (1H, d, 
J=2.3), 7.74 (1H, d, J=2.3), 7.38-7.44 (5H, m) 5.16 (2H, s), 5.02 (2H brs). 13C NMR (CDCl3, 
100 MHz) δ 144.1, 143.3, 138.9, 135.4, 129.0, 128.9, 128.3, 128.1, 106.7, 178.5, 71.5. 
IR (neat) νmax 3476, 3379, 3359, 3091, 3056, 3030, 2357, 2333, 1602, 1568, 1497, 1451, 
1425, 1386, 1282, 1237, 1099, 1037, 1025, 869, 849, 819, 740, 726, 692 cm-1.  HRMS 
(ES+) calculated for C13H12IN2O3 (M+H)+ 370.9887 found 370.9890. 
Methyl 3-[2-Amino-3-(phenylmethoxy)-5-nitrophenyl]-2-propynoic acid (22)  
21 (40.8 g, 110 mmol) was dissolved in anhydrous DMF (1225 mL). The resulting 
solution was degassed with a stream of N2 for 30 min prior to addition of methyl 
propiolate (37.1 mL, 441 mmol), Pd(PPh3)2Cl2 (3.87 g, 5.51 mmol),  ZnBr2 (99 g, 441 
mmol), and DIPEA (77 ml, 441 mmol) at room temperature . The reaction mixture was 
then heated to 66 oC and stirred overnight under N2. After cooling to room 
temperature the reaction was poured over crushed ice, and the resulting chocolate 
colour precipitate collected by filtration. The reaction was repeated with 51 g of 21, 
and the precipitates were combined prior to adsorption on to 250 g of silica. Elution 
through a 1 Kg silica plug with 50% ethyl acetate and hexane afforded 62 g of 22 as an 
orange amorphous solid (77% yield). Rf  0.16 (20 % EtOAc in hexane); mp 136-139 oC.  
1H NMR (CDCl3, 400 MHz) δ 8.06 (1H, d, J=2.4), 7.76 (1H, d, J=2.4), 7.38-7.45 (5H, m), 
5.32 (2H, brs), 5.17 (2H, s), 3.86 (3H, s). 13C NMR (CDCl3, 100 MHz) δ 154.1, 146.7, 
144.5, 137.8, 135.2, 129.1, 129.0, 128.1, 123.0, 108.3, 101.0, 87.1, 81.1, 71.5, 53.1. IR 
(neat) νmax 3499, 3391, 3351, 3087, 3063, 3030, 2951, 2204, 1698, 1611, 1455, 1430, 
1393, 1325, 1299, 1237, 1215, 1148, 1093, 1040, 1028, 1001, 886, 859, 755, 740, 731, 
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694, 657, 612 cm-1. HRMS (ES+) calculated for C17H15N2O5 (M+H)+ 327.0975 found 
327.0979. 
1-(1,1-Dimethylethyl)-2-methyl 5-nitro-6-(phenylmethoxy)indole-1,2-dicarboxylate 
(24)  
22 (60 g, 184 mmol) in anhydrous THF (858 mL) was treated with 1M TBAF in THF 
solution (368 mL, 368 mmol) and refluxed at 66 oC for 1 h. After cooling to room 
temperature the THF was removed by rotary evaporation under reduced pressure. 
The residue was dissolved in ethyl acetate (1000 mL) and washed 3 times with water 
(1000 mL). Concentration of the ethyl acetate followed by co-evaporation of the 
residue with CH2Cl2 afforded crude product as a dark purple foam. The foam was 
dissolved in CH2Cl2 (1000 mL) and treated with Boc2O (80 g, 368 mmol), and DMAP 
(22.46 g, 184 mmol) at room temperature for 1.5 h.  Removal of the CH2Cl2 gave a dark 
foam which was purified by silica gel chromatography using an automated flash 
chromatography system. The crude was dry loaded on to a 1.5 kg pre-packed silica 
column adsorbed on to 200 g of silica. A linear gradient of 0 to 30% ethyl acetate in 
hexane was run over 23 column volumes and then held at 30% ethyl acetate until 
complete elution of the product. Removal of the solvent afford 31 g of 24 as an orange 
amorphous solid (39% yield of 2 steps). Rf  0.33 (20 % EtOAc in hexane); mp 168-171 
oC. 1H NMR (CDCl3, 400 MHz) δ 8.26 (1H, d, J=1.9), 7.67 (1H, d, J=1.9), 7.49-7.45 (2H, 
m), 7.41-7.34 (3H, m), 7.33 (1H, s) 5.33 (2H, s), 3.94 (3H, s), 1.47 (9H, s). 13C NMR 
(CDCl3, 100 MHz) δ 160.5, 149.3, 145.6, 143.6, 135.2, 130.2, 128.9, 128.7, 128.2, 126.4, 
112.7, 112.5, 102.2, 86.5, 71.3, 52.5, 27.9, 27.3. IR (neat) νmax 3127, 3099, 3050, 2981, 
2949, 1765, 1722, 1586, 1512, 1437, 1388, 1372, 1325, 1252, 1223, 1151, 1115, 1073, 
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982, 875, 840, 822, 801, 778, 766, 742, 729, 697, 606 cm-1. HRMS (ES+) calculated for 
C22H23N2O7 (M+H)+ 427.1500 found 427.1499. 
1-(1,1-Dimethylethyl)-2-methyl 5-[[(1,1-dimethylethoxy)carbonyl]amino]-4-iodo-7-
(phenylmethoxy)indole-1,2-dicarboxylate (26) 
24 (15 g, 35.2 mmol) was dissolved in THF (293  ml) and treated with zinc powder (34.5 
g, 528 mmol), NH4Cl (18.82 g, 352 mmol), Boc2O (23.03 g, 106 mmol), DMAP (430 mg, 
3.52 mmol), and water (58.6 mL). The resulting suspension was stirred vigorously at 
room temperature overnight.  After removal of the zinc by filtration, the THF was 
evaporated and the residue taken up in ether (500 mL). The ether was washed 3 times 
with water (250 mL) and died over MgSO4. Co-evaporation with CH2Cl2 gave crude 25 
as a light brown foam. The reaction was repeated on the same scale and the crudes 
combined and dissolved in DMF (352 mL). H2SO4 (0.375 mL, 7.04 mmol) was added 
followed by portionwise addition of NIS (23.75 g, 106 mmol) at room temperature. 
After 3 h the reaction was diluted with Et2O (1000 mL), and washed once with 50% 
saturated brine in water (1000 mL), twice with water (1000 mL), and once with 
saturated brine (1000 mL). The first wash was back extracted 3 times with Et2O (500 
mL), which was subsequently combined and washed twice with saturated brine (1000 
mL). All the Et2O was combined and concentrated to give a dark red foam which was 
purified by silica gel chromatography using an automated flash chromatography 
system. The crude was dry loaded on to a 750 g pre-packed silica column adsorbed on 
to 170 g of Celite. A linear gradient of 0 to 20% ethyl acetate in hexane was run over 
16 column volumes. Removal of the solvent afforded 26 g of 26 as an off white foam 
which dried to an amorphous solid (59% yield over 3 steps). Rf 0.37 (20 % EtOAc in 
hexane); mp 158-161 oC.  1H NMR (CDCl3, 400 MHz) δ 7.79 (1H, brs), 7.49-7.46 (2H, m), 
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7.30-7.38 (3H, m), 7.09 (1H, s), 6.77 (1H, brs), 5.24 (2H, s), 3.91 (3H, s), 1.54 (9H, s), 
1.41 (9H, s). 13C NMR (CDCl3, 100 MHz) δ  160.9, 153.1, 149.9, 146.6, 136.0, 134.7, 
131.5, 128.7, 128.6, 128.4, 127.8, 123.7, 114.6, 102.6, 85.6, 81.0, 71.1, 52.3, 28.5, 27.3. 
IR (neat) νmax 3355, 2984, 2933, 1763, 1725, 1716, 1615, 1575, 1541, 1505, 1449, 1393, 
1361, 1338, 1310, 1256, 1221, 1152, 1080, 980, 908, 878, 843, 817, 758, 723, 693 cm-
1. HRMS (ES+) calculated for C27H32O7N2I (M+H)+ 623.1249 found 623.1246. 
1-(1-,1-Dimethylethyl)-2-methyl 5-[(3-chloro-2-propenyl)[(1,1-
dimethylethoxy)carbonylamino]-4-iodo-7-(phenylmethoxy)indole-1,2-
dicarboxylate (27) 
26 (26 g, 41.8 mmol) was dissolved in DMF (418 mL) and treated with t-BuOK (9.37 g, 
84 mmol) and technical grade (90%) 1,3-dichloropropene as a mixture of cis and trans 
isomers (12.90 mL, 125 mmol). After stirring for 1.5 h with the vessel submerged in a 
room temperature water bath, the reaction was cooled to 0 oC and quenched with 
saturated aqueous NH4Cl (20 mL). The mixture was diluted with Et2O (1000 mL), and 
washed twice with of 50% saturated brine in water (1000 mL), and once with saturated 
brine (1000 mL). The Et2O was dried over MgSO4, concentrated, and co-evaporated 
with CH2Cl2 6 times to afford a brown foam which was purified by silica gel 
chromatography using an automated flash chromatography system. The crude was 
dry loaded on to a 220 g pre-packed silica column adsorbed on silica. A linear gradient 
of 0 to 10% ethyl acetate in hexane was run over 16 column volumes. Removal of the 
solvent afforded 18 g of 27 as a light brown foam which dried to an amorphous solid 
(62% yield - mixture of E/Z isomers). Rf 0.31 (20 % EtOAc in hexane); mp 104-106 oC.  
1H NMR (CDCl3, 400 MHz, mixture of E/Z isomers) δ 7.28-7.44 (5H, m) 7.18 (1H, s), 
6.65-6.47 (1H, m), 5.80-6.00 (2H, m]), 5.17-5.28 (2H, m), 4.46 & 4.18 (1H, m), 4.33 & 
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3.73 (1H, m), 3.93 (3H, s), 1.53 (9H, s), 1.29 & 1.27 (9H, s). 13C NMR (CDCl3, 100 MHz) 
δ 160.9, 154.2, 150.0, 145.7, 138.7, 135.9, 132.2, 128.9, 128.4, 128.0, 127.5, 125.4, 
121.8, 120.7, 115.3, 109.7 86.0, 83.9, 80.6, 70.7, 52.4, 49.5, 46.2, 28.4, 27.3. IR (neat) 
νmax 2976, 2921, 1775, 1731, 1702, 1694, 1571, 1535, 1467, 1454, 1435, 1391, 1372, 
1299, 1251, 1227, 1150, 1118, 1077, 978, 932, 885, 842, 829, 782, 764, 739, 731, 699 
cm-1. HRMS (ES+) calculated for C30H35O7 N2ClI (M+H)+ 697.1172 found 697.1174. 
3.6-Bis(1,1-dimethylethyl)-2-methyl 8-(chloromethyl)-7,8-dihydro-4-
(phenylmethoxy)benzo[1,2-b: 4,3-b’]dipyrrole-2,3,6-tricarboxylate (28) 
27 (9 g, 12.9 mmol) was dissolved in anhydrous toluene and degassed with a stream 
of N2 for 45 min prior to addition of AIBN (0.530 g, 3.23 mmol) and 
Tris(trimethylsilyl)silane (TTMSS) (4.38 mL, 14.20 mmol). The resulting solution was 
refluxed a 90 oC under N2. After 1 h the reaction was allowed to cool to room 
temperature before being concentrated and subjected directly to silica gel column 
chromatography using an automated flash chromatography system. A 120 g pre-
packed silica column was used, and 0% ethyl acetate in hexane run for 5 column 
volumes rising to 10% linearly over the subsequent 5 column volumes, holding at 10% 
until complete elution of the product. The reaction was repeated on the same scale 
and the products combined, affording 10.28 g of 28 as white foam which dried to an 
amorphous solid (70% yield). Rf 0.30 (20 % EtOAc in hexane); mp 115-118 oC. 1H NMR 
(DMSO-d6, 400 MHz) δ 7.69 (1H brs), 7.47-7.29 (6H, m), 5.27 (2H, s), 4.13 (1H, t, J=9.7), 
4.06-3.89 (4H, m), 3.87 (3H, s), 1.48 (9H, s), 1.39 (9H, s). 13C NMR (DMSO- d6, 100 MHz) 
δ 160.4, 151.4, 149.5, 145.1, 136.2, 128.4, 128.0, 127.9, 123.5, 113.2, 108.5, 97.4, 85.0, 
80.3, 69.7, 52.3, 52.2, 47.6, 40.7 (obscured by DMSO peak observed by HSQC), 28.0, 
26.8, 22.0. IR (neat) νmax 3002, 2977, 2921, 2357, 1782, 1720, 1698, 1593, 1538, 1494, 
30 
 
1494, 1439, 1417, 1379, 1343, 1241, 1214, 1141, 1089, 1022, 988, 918, 899, 836, 765, 
745, 712, 699, 691, 664 cm-1.  HRMS (ES+) calculated for C30H36O7N2Cl (M+H)+ 
571.2206 found 571.2201. 
8-(Chloromethyl)-7,8-dihydro-4-(phenylmethoxy)benzo[1,2-b: 4,3-b’ ]dipyrrole-3,6-
dicarboxylic acid 3,6-bis(dimethylethyl)ester (29)  
28 (10.28 g, 18.00 mmol) was dissolved in a mixture of THF (167 ml) and MeOH (111 
ml) and treated with a saturated aqueous solution of LiOH (56 mL) drop wise. After 3 
h the THF and MeOH was removed under reduced pressure, and the residue diluted 
with water (100 mL). Acidification with 5 M HCl promoted the precipitation 29 as a 
white solid which was collected by filtration. Recovery from the filter by dissolution in 
ethyl acetate and co-evaporation with CH2Cl2 afforded 10 g of 29 as a light green foam 
which dried to an amorphous solid (100% yield). Rf  0.48 (10 % MeOH in CH2Cl2); mp 
174-178 oC. 1H NMR (DMSO- d6, 400 MHz) δ 13.43 (1H, brs), 7.69 (1H, brs), 7.49-7.29 
(6H, m), 5.26 (2H, s), 4.13 (1H, t, J=9.7), 4.05-3.87 (4H, m), 1.49 (9H, s), 1.37 (9H, s). 13C 
NMR (DMSO- d6, 100 MHz) δ 161.5, 151.5, 149.1, 136.2, 129.5, 128.4, 128.0, 127.6, 
123.6, 123.4, 122.4, 107.7 97.1, 84.6, 80.0, 69.7, 52.2, 47.6, 40.8 (obscured by DMSO 
peak observed by HSQC), 28.1, 26.8, 22.0.  IR (neat) νmax 2976, 2929, 2361, 2328, 1770, 
1694, 1683, 1593, 1538, 1495, 1418, 1393, 1368, 1251, 1142, 1085, 1013, 978, 908, 
942, 792, 745, 695, 668 cm-1. HRMS (ES+) calculated for C29H34O7N2Cl (M+H)+ 557.2049 
found 557.2044. 
8-(chloromethyl)-7,8-dihydro-4-(phenylmethoxy)benzo[1,2-b: 4,3-b’]dipyrrole-2,6-
dicarboxylic acid 6-(9H-fluoren-9-ylmethyl) ester (7) 
29 (10 g, 17.95 mmol) was dissolved in 4 M HCl in dioxane (180 mL) and stirred at 
room temperature overnight. Following removal of the dioxane under reduced 
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pressure, the residue was dissolved in THF (269 mL). The resulting solution was cooled 
to 0 oC, before being treated with NaHCO3 (4.52 g, 53.9 mmol) in water (90 mL), 
followed by Fmoc-Cl (4.64 g, 17.95 mmol) dropwise in THF (100 mL). After 5 min the 
reaction was quenched with MeOH (2 mL), and the THF and MeOH removed under 
reduced pressure. The remaining mixture was acidified with 2 M HCl, and extracted 3 
times with 2-MeTHF, and dried over MgSO4. Crude 7 was purified by silica gel 
chromatography using an automated flash chromatography system. The crude was 
dry loaded on to a 220 g pre-packed silica column adsorbed on to 18 g of silica. A linear 
gradient of 0 to 5% MeOH in CH2Cl2 was run. Removal of the solvent afforded 8.3 g of 
racemic 7 as a light green/brown foam which dried to an amorphous solid (80% yield 
over 2 steps). Rf 0.42 (10 % MeOH in CH2Cl2); 125-128 oC. 1H NMR (DMSO- d6, 400 
MHz) δ 12.97 (1H, brs), 11.90 (1H, s), 7.90 (2H, d, J=6.7), 7.74-7.68 (2H, m), 7.67-7.57 
(2H, m), 7.53-7.23 (8H, m), 7.20 (1H, d, J=1.8), 5.35-5.84 (2H, brs, [rotameric 
coalescence observed at 333K, δ 5.17, 2H, s]), 4.74-4.31 (3H, m, [rotameric 
coalescence observed at 333K, δ 4.55, 2H, app quin, δ 4.39, 1H, t, J=6.6]), 4.23-4.14 
(1H, m), 4.10-3.94 (3H, m), 3.93-3.84 (1H, m). 13C NMR (DMSO- d6, 100 MHz) δ 162.5, 
152.0, 145.6, 143.8, 140.8, 136.8, 129.9, 128.2, 127.8, 127.6, 127.4, 127.2, 125.6, 
125.1, 124.1, 120.2, 112.7, 105.8, 95.4, 69.5, 66.6, 51.9, 47.6, 46.7, 41.0, 34.4. IR (neat) 
νmax 2950, 2367, 2320, 1694, 1682, 1593, 1538, 1441, 1404, 1318, 1247, 1218, 1171, 
1131, 1085, 1028, 966, 903, 827, 737, 696, 667, 621 cm-1. HRMS (ES-) calculated for 
C34H26O5N2Cl (M-H)- 577.1536 found  577.1527.  
Preparative chiral resolution of 7 was achieved using super critical fluid 
chromatography. Separation was affected using a Chiralpak AD-H column (250 x 30 
mm, 5 micron), and an isocratic flow of 50% CO2, and 50% IPA containing 0.1% TFA, at 
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45 mL per min. The back pressure was regulated at 10 MPa, and column temperature 
controlled at 40 oC. A racemate of 7 (9.8 g) was dissolved in THF:MeOH 1:1 (100 mL), 
and 1.25 mL (125 mg) injected every 9 min. Fractions were monitored by UV (220 nm), 
collected, combined and dried to afford 2.82 g of peak 1 (5.5 min), and 3.1 g of peak 2 
(7 min), both as cream amorphous solids (α = 1.27). Peak 1 [α]25D –20 (c 0.05, DMF); 
mp 204-207 oC. Peak 2 [α]25D +20 (c 0.05, DMF); mp 204-207 oC . 
8-(Chloromethyl)-7,8-dihydro-4-hydroxybenzo[1,2-b:4,3-b']dipyrrole-2,6(3H)-
dicarboxylic acid,  2,6-dimethyl ester (30) 
28 (50 mg, 0.087 mmol) was dissolved in 4 M HCl in EtOAc (5 mL) containing TIPS (500 
µL) and the solution was stirred overnight at room temperature. After removal of the 
solvent under reduced pressure, the residue was taken up in DMF (7 mL), and cooled 
to 0 oC. The solution was treated with DIPEA (30 µL, 0.17 mmol), and AcCl (6 µL, 0.087 
mmol) and stirred under N2. After 2 h the reaction was poured over crushed ice and 
the product was collected as a beige precipitate. This was dissolved in a 1:1 mixture 
of THF and MeOH (2 mL) and added to a suspension of 10 % Pd/C (20 mg) in 25 % 
aqueous ammonium formate (300 µL) under N2.  After 1 h, the reaction was filtered 
through Celite. Flash chromatography (silica gel, 7 x 1 cm, 5% MeOH in CH2Cl2) 
afforded 17 mg 30 as a white amorphous solid (60% yield over 3 steps). 1H NMR 
(DMSO- d6, 400 MHz) δ 11.55 (1H, brs), 9.72 (1H, s), 7.75 (1H, s), 7.22 (1H, app d, 
J=2.10), 4.31 (1H, t, J=11.6), 4.10-3.96 (3H, m), 3.91-3.87 (1H, m), 3.85 (3H, s), 2.15 
(3H, s). 13C NMR (DMSO-D6, 100 MHz) δ 167.4, 161.4, 143.6, 138.0, 127.7, 125.4, 
124.0, 111.7, 106.0, 99.7, 53.2, 51.8, 47.7, 41.5, 24.1. HRMS (ES+) calculated for 
C15H16ClN2O4 (M+H)+ 323.0793 found 323.0797. 
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8-(Chloromethyl)-7,8-dihydro-4-hydroxybenzo[1,2-b:4,3-b']dipyrrole-2,6(3H)-
dicarboxylic acid,  6-methyl ester (31)  
The benzyl protected precursor to 30 (57 mg, 0.14 mmol) was dissolved in a 3:2:1 
mixture of THF:MeOH:H2O (6 mL), and treated with LiOH.H2O (110mg, 2.62 mmol) 
overnight at room temperature. The organic solvents were removed under reduced 
pressure, and the residue diluted with 1 M HCl (10 mL). The mixture was cooled to 4 
oC for 72 hrs, and the product was collected as a beige precipitate by centrifugation. 
This was dissolved in a 1:1 mixture of THF and MeOH (2 mL) and added to a suspension 
of 10% Pd/C (20 mg) in 25 % aqueous ammonium formate (300 µL) under N2. After 1 
h the reaction was filtered through Celite and the crude purified by preparative HPLC. 
Lyophilization afforded 6.5 mg of 31 as a tan amorphous solid (15% yield over 2 steps). 
1H NMR (DMSO- d6, 400 MHz) δ 12.92 (1H, brs), 11.33 (1H, s), 9.62 (1H, s), 7.72 (1H, 
s), 7.13 (1H, s), 4.37-4.25 (1H, m), 4.12-3.95 (3H, m),  3.92-3.81 (1H, m), 2.15 (3H, s). 
13C NMR (DMSO-D6, 100 MHz) δ 167.4, 162.5, 143.5, 137.9, 129.1, 125.1, 124.1, 111.6, 
105.6, 99.5, 53.2, 47.7, 41.5, 24.1. HRMS (ES+) calculated for C14H14ClN2O4 (M+H)+ 
309.0637 found 309.0637. 
Solid phase synthesis. 
All amino acids used were of the natural L configuration. (-)8S-7 is used in all solid 
phase synthesis work 
Representative example for compounds 8-13 – compound (8): H-Ala-2Cl-trt resin (53 
mg, 0.039 mmol Ala, [manufacturer’s resin loading 0.73 mmol/g]) was prepared for 
coupling by swelling in CH2Cl2 for 30 min followed by DMF for a further 30 min. 7 (25 
mg, 0.043 mmol) was dissolved in 2 mL of DMF and treated with HATU (13 mg, 0.043 
mmol) and DIPEA (16 µL, 0.086 mmol). After 10 s the resulting solution was added to 
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the resin and the mixture shaken overnight. The resin was washed 6 times with DMF 
(10 mL) and removal of the Fmoc protection of the indoline nitrogen affected with 
piperidine in DMF (3 mL 40%, 10 min, 3 mL 20% 5 min twice). Following Fmoc 
deprotection the resin was washed 6 times with DMF (10 mL) and 3 times with 
anhydrous DMF (10 mL). The resin was placed under an atomsphere of N2 and treated 
with anhydrous DMF (2 mL), DIPEA (75 µL, 0.43 mmol), and AcCl (16 µL, 0.225 mmol). 
After 1 h of shaking the resin was washed 6 times with DMF (10 mL) and 6 times with 
CH2Cl2. Cleavage was affected by addition of a solution of 1% TFA, 10% TIPS in CH2Cl2 
(10 mL). After 2 h of shaking the cleavage mixture was filtered. The resin was rinsed 3 
times with CH2Cl2 (3 mL) and the combined filtrates were concentrated to dryness by 
rotary evaporation under vacuum. To ensure full recovery of the product the resin was 
soaked in THF:MeOH (10 mL), and after filtering this was combined with the rest of 
the cleavage product and again evaporated to dryness.  The crude cleavage product 
was dissolved in THF:MeOH (2 mL) and treated with a slurry of  10 % Pd/C (20mg) in a 
25% aqueous solution of ammonium formate (300 µL) under N2. After 1 h the Pd/C 
was removed by filtering through a plug of Celite.  Flash chromatography (silica gel, 7 
x 1 cm, 0% to 30% MeOH in EtOAc) and trituration with hexane, afforded 10 mg of 8 
as a beige amorphous solid (69% yield). 1H NMR (DMSO- d6, 400 MHz) δ 11.23 (1H, s), 
9.70, (1H, s), 8.57 (1H, d, J=7.4), 7.70 (1H, s), 7.21 (1H, appt d, J=2.1), 4.44 (1H, appt 
quin, J=7.4), 4.33 (1H, appt t, J=11.7], 4.11-4.06 (1H, m), 4.04-3.96 (2H, m), 3.89-3.82 
(1H, m), 2.15 (3H, s), 1.41 (3H, d, J=7.4). 13C NMR (observed by DEPT-ed-HSQC) (DMSO- 
d6, 100 MHz) δ 104.0 (CH1), 100.2 (CH1), 53.3 (CH2), 50.4 (CH1), 47.7 (CH2), 41.6 
(CH1), 24.2 (CH3), 20.0 (CH3). HRMS (ES+) calculated for C17H19ClN3O5 (M+H)+ 
380.1008 found 380.1004.   
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(9): same as representative example using H-β-Ala-2Cltrt resin (53 mg, 0.039 mmol β-
Ala, [manufacturer’s resin loading 0.73 mmol/g]). Flash chromatography (silica gel, 7 
x 1 cm, 0% to 30% MeOH in EtOAc) and trituration with hexane afforded 12 mg of 9 
as a beige amorphous solid (81% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.29 (1H, 
brs), 11.18 (1H, s), 9.69 (1H, s), 8.45 (1H, brs), 7.69 (1H, s), 7.11 (1H, s), 4.35-4.28 (1H, 
m), 4.07-3.95 (3H, m), 3.87-3.81 (1H, m), 3.48 (2H, obscured by H2O peak observed by 
HSQC and COSY), 2.53 (2H, obscured by DMSO peak observed by HSQC and COSY), 
2.15 (3H, s). 13C NMR (observed by DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 101.4 
(CH1), 98.8 (CH1), 53.3 (CH2), 47.4 (CH2), 41.8 (CH1), 35.2 (CH2), 33.9 (CH2), 24.2 
(CH3). HRMS (ES+) calculated for C17H19ClN3O5 (M+H)+ 380.1008 found 380.1009. 
(10): same as representative example using H-Phe-2Cltrt resin (53 mg, 0.039 mmol 
Phe, [manufacturer’s resin loading 0.73 mmol/g]) Flash chromatography (silica gel, 7 
x 1 cm, 0% to 10% MeOH in EtOAc) and trituration with hexane, afforded 11 mg of 10 
as a beige amorphous solid (56% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.87 (1H, 
brs), 11.20 (1H, s), 9.70 (1H, s), 8.65 (1H, d, J=8.1), 7.70 (1H, s) 7.32-7.25 (4H, m), 7.21-
7.16 (2H, m), 4.72-4.65 (1H, m), 4.36-4.27 (1H, m), 4.10-3.97 (3H, m), 3.89-3.82 (1H, 
m), 3.24-3.16 (1H, m), 3.06-2.98 (1H, m), 2.15 (3H, s) . 13C NMR (observed by DEPT-ed-
HSQC) (DMSO- d6, 100 MHz) δ 128.7 (CH1), 128 (CH1), 126.2 (CH1), 102.0 (CH1), 98.6 
(CH1), 53.5 (CH1), 52.9 (CH2), 47.1 (CH2), 41.5 (CH1),  36.5 (CH2), 23.8 (CH3). HRMS 
(ES+) calculated for C23H23O5N3Cl (M+H)+ 456.1321 found 456.1317.   
(11): same as representative example using H-Ser(tBu)-2Cltrt resin (51 mg, 0.039 
mmol Ser, [manufacturer’s resin loading 0.76 mmol/g]) Preparative HPLC (see general 
Prep HPLC method) and lyophilization, afforded 7.5 mg of 11 as a beige amorphous 
solid (48% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.76 (1H, brs), 11.35 (1H, s), 9.72 
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(1H, s), 8.49 (1H, d, J= 8.3), 7.71 (1H, s), 7.24 (1H, s), 5.01 (1H, brs), 4.58-4.48 (1H, m), 
4.37-4.28 (1H, m), 4.14-3.97 (3H, m), 3.90-3.76 (3H, m), 2.15 (3H, s). 13C NMR 
(observed by DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 102.0 (CH1), 98.3 (CH1), 61.0 
(CH2), 55.0 (CH1), 53.0 (CH2), 47.2 (CH2), 41.6 (CH1), 23.8 (CH3). HRMS (ES+) 
calculated for C17H19ClN3O6 (M+H)+ 396.0957 found 396.0956. 
(12): same as representative example using H-Glu(OtBu)-2Cltrt resin (59 mg, 0.039 
mmol Glu, [manufacturer’s resin loading 0.65 mmol/g]). Preparative HPLC (see general 
Prep HPLC method) and lyophilization, afforded 6.5 mg of 12 as a beige amorphous 
solid (38% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.51 (2H, brs), 11.25 (1H, s), 9.73 
(1H, s), 8.52 (1H, brs), 7.70 (1H, s), 7.21 (1H, s), 4.49-4.30 (2H, m), 4.18-3.93 (3H, m), 
3.91-3.80 (1H, m), 2.43-2.35 (2H, m), 2.21-2.04 (4H, m), 1.97-1.86 (1H, m). 13C NMR 
(observed by DEPT-ed-HSQC) (DMSO- d6 , 100 MHz) δ 102.2 (CH1), 98.8 (CH1), 53.1 
(CH2), 51.3 (CH1), 47.2 (CH2), 41.7 (CH1), 30.1 (CH2), 26.1 (CH2), 23.9 (CH3). HRMS 
(ES+) calculated for C19H21ClN3O7 438.1063 (M+H)+ found 438.1053. 
(13): same as representative example using H-Lys(Boc)-2Cltrt resin (53 mg, 0.039 
mmol Lys, [manufacturer’s resin loading 0.73 mmol/g]). Preparative HPLC (see general 
Prep HPLC method) and lyophilization, afforded 3.3 mg of 13 as a beige amorphous 
solid (19% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.79 (1H brs), 11.28 (1H, s), 9.79 
(1H, s), 8.54 (1H, d, J=8.3), 7.73-7.69 (2H, brs), 7.71 (1H, s), 7.22 (1H, s), 4.46-4.38 (1H, 
m), 4.37-4.28 (1H, m), 4.14-3.95 (3H, m), 3.91-3.83 (1H, m), 2.82-2.76 (2H, m), 2.16 
(3H, s), 1.86-1.74 (2H m), 1.60-1.54 (2H, m), 1.47-1.41 (2H m). 13C NMR (observed by 
DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 102.2 (CH1), 98.8 (CH1), 53.0 (CH2), 51.6 
(CH1), 47.2 (CH2), 41.5 (CH1), 38.4 (CH2), 30.3 (CH2), 26.3 (CH2), 24.0 (CH3), 22.5 
(CH2). HRMS (ES+) calculated for C20H26ClN4O5 437.1586 (M+H)+ found 437.1593. 
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(14):Representative example for compounds 14-16. H-Lys(Boc)-2Cltrt resin (53 mg, 
0.039 mmol Lys, [manufacturer’s resin loading 0.73 mmol/g]) was prepared for 
coupling by swelling in CH2Cl2 for 30 min followed by DMF for a further 30 min. 7 (25 
mg, 0.043 mmol) was dissolved in 2 mL of DMF and treated with HATU (13 mg, 0.043 
mmol) and DIPEA (16 µL, 0.086 mmol). After 10 s the resulting solution was added to 
the resin and the mixture shaken overnight. The resin was washed 6 times with DMF 
(10 mL) and removal of the Fmoc protection of the indoline nitrogen affected with 
piperidine in DMF (3 mL 40% 10 min, 3 mL 20% 5 min twice). Following Fmoc 
deprotection the resin was washed 6 times with DMF (10 mL). 5-Methoxyindole-2-
carboxylic acid (38 mg, 0.199 mmol) was dissolved in 2 mL of DMF and treated with 
HATU (73 mg, 0.191 mmol) and DIPEA (70 µL, 0.401 mmol). After 10 s the resulting 
solution was added to the resin and the mixture shaken overnight. The resin was 
washed 6 times with DMF (10 mL) and 6 times with CH2Cl2. Cleavage was affected by 
addition of a solution of 10% TFA, 10% TIPS in CH2Cl2 (10 mL). After shaking for 2 h, 
the cleavage mixture was filtered. The resin was rinsed 3 times with CH2Cl2 (3 mL) and 
the combined filtrates were concentrated to dryness by rotary evaporation under 
vacuum. To ensure full recovery of the product the resin was soaked in THF:MeOH (10 
mL), and after filtering this was combined with the rest of the cleavageproduct and 
again evaporated to dryness.  The crude cleavage product was dissolved in THF:MeOH 
(2 mL) and treated with a slurry of  10% Pd/C (30mg) in a 25% aqueous solution  
ammonium formate (500 µL) under N2. After 1 h the Pd/C was removed by filtering 
through a plug of Celite. Preparative HPLC (see general Prep HPLC method) and 
lyophilization, afforded 4.4 mg of 14 as a beige amorphoussolid (20% yield). 1H NMR 
(DMSO- d6, 400 MHz) δ 11.56, (1H, s), 11.38 (1H, brs), 9.89 (1H, brs), 8.59 (1H brs), 
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7.76 (1H, brs), 7.59 (2H brs), 7.38 (1H, d, J=8.9), 7.26 (1H, s), 7.15 (1H, d, J= 2.2), 7.02 
(1H, d, J=1.4), 6.89 (1H, dd, J=8.9, 2.2), 4.82-4.67 (1H, m), 4.51-4.39 (2H, m), 4.18-4.03 
(2H, m), 3.99-3.91 (1H, m), 3.78 (3H, s), 2.84-2.75 (2H, m), 1.92-1.74 (2H, m), 1.64-1.55 
(2H, m), 1.49-1.42 (2H, m). 13C NMR (observed by DEPT-ed-HSQC) (DMSO- d6, 100 
MHz) δ 114.8 (CH1), 112.8 (CH1), 104.5 (CH1), 102.4 (CH1), 101.8 (CH1), 99.5 (CH1), 
54.9 (CH3), 54.4 (CH2), 51.8 (CH1), 47.1 (CH2), 42.0 (CH1), 38.4 (CH2), 3.3 (CH2), 26.4 
(CH2), 22.4 (CH2). HRMS (ES+) calculated for C28H31ClN5O6 568.1957 (M+H)+ found 
568.1949. 
(15): Same as representive example using H-Ser(tBu)-2Cltrt resin (56 mg, 0.039 mmol 
Lys, [manufacturer’s resin loading 0.76 mmol/g]). Preparative HPLC (see general Prep 
HPLC method) and lyophilization, afforded 3.3 mg of 15 as a beige amorphous solid 
(16% yield). 1H NMR (DMSO- d6, 400 MHz) δ 11.54 (1H, s), 11.43 (1H, s), 9.80 (1H, s), 
8.52 (1H, d, J=7.4), 7.77 (1H, brs), 7.38 (1H, d, J= 8.6), 7.29 (1H, d, J=1.4), 7.15 (1H, d, 
J=2.3), 7.02 (1H, d, J=1.3), 7.89 (1H, dd, J= 8.6, 2.3), 4.79-4.71 (1H, m), 4.57-4.50 (1H, 
m), 4.47-4.37 (1H, m), 4.17-4.04 (2H, m), 3.99-3.89 (1H, m), 3.82-3.76 (2H, m), 3.78 
(3H, s). 13C NMR (observed by DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 114.6 (CH1), 
112.8 (CH1), 104.2 (CH1), 102.4 (CH1), 101.7 (CH1), 99.5 (CH1), 61.1 (CH2), 55.0 (CH3), 
54.8 (CH1), 54.4 (CH2), 47.0 (CH2), 42.0 (CH1). HRMS (ES-) calculated for C25H22ClN4O7 
525.1182  (M-H)- found 525.1187. 
(16): same as representative example using H-Ala-2Cltrt resin (58 mg, 0.039 mmol Ala, 
[manufacturer’s resin loading 0.72 mmol/g]). Reverse phase flash chromtography (see 
general reverse phase flash chromotography method) and lyophilization, afforded 7 
mg of 16 as a beige amorphous solid (35% yield). 1H NMR (DMSO- d6, 400 MHz) δ 12.67 
(1H, Brs), 11.5 (1H, s), 11.32 (1H, s), 9.82 (1H, s), 8.62, (1H, d, J=7.0), 7.76 (1H, brs), 
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7.38 (1H, d, J=8.9), 7.27 (1H, s), 7.15 (1H, s), 7.02 (1H, s), 6.89 (1H, d, J=8.9), 4.81-4.71 
(1H, m), 4.50-4.39 (2H, m), 4.16-4.06 (2H, m), 3.98-3.91 (1H, m), 3.78 (3H, s), 1.42 (3H, 
d, J=7.3). 13C NMR (observed by DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 114.7 (CH1), 
112.7 (CH1), 104.4 (CH1), 102.2 (CH1), 101.8 (CH1), 99.5 (CH1), 54.9 (CH3), 54.4 (CH2), 
47.5 (CH1), 46.9 (CH2), 42.0 (CH1), 16.9 (CH3). HRMS (ES-) calculated for C25H22ClN4O6 
509.1233 (M-H)- found 509.1234. 
(17): H-Ala-2Cltrt resin (58 mg, 0.039 mmol Ala, [manufacturer’s resin loading 0.72 
mmol/g]) was prepared for coupling by swelling in CH2Cl2 for 30 min followed by DMF 
for a further 30 min. 7 (25 mg, 0.043 mmol) was dissolved in 2 mL of DMF and treated 
with HATU (13 mg, 0.043 mmol) and DIPEA (16 µL, 0.086 mmol). After 10 s the 
resulting solution was added to the resin and the mixture shaken overnight. The resin 
was washed 6 times with DMF (10 mL) and removal of the Fmoc protection of the 
indoline nitrogen affected with piperidine in DMF (3 mL 40% 10 min, 3 mL 20% 5 min 
twice). Following Fmoc deprotection the resin was washed 6 times with DMF (10 mL). 
5-Methoxyindole-2-carboxylic acid (38 mg, 0.199 mmol) was dissolved in 2 mL of DMF 
and treated with HATU (73 mg, 0.191 mmol) and DIPEA (70 µL, 0.401 mmol). After 10 
s the resulting solution was added to the resin and the mixture shaken overnight. The 
resin was washed 6 times with DMF (10 mL) and 6 times with CH2Cl2 (10 mL). Cleavage 
was affected by addition of a solution of 1% TFA, 10% TIPS in CH2Cl2 (10 mL). After 
shaking for 2 h the cleavage mixture was filtered. The resin was rinsed 3 times with 
CH2Cl2 (3 mL) and the combined filtrates were concentrated to dryness by rotary 
evaporation under vacuum. To ensure full recovery of the product the resin was 
soaked in THF:MeOH (10 mL), and after filtering this was combined with the rest of 
the cleavage product and again evaporated to dryness. The crude was dissolved in 
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DMF (1 mL), and treated with HATU (16 mg, 0.042 mmol), and DIPEA (20 µL, 0.12 
mmol). After 10 s the resulting solution was treated with 3-(dimethylamino)-1-
propylamine (30 µL, 0.24 mmol) and stirred at room temperture for 2 h, prior to 
preciptation with cold H2O (15 mL), and collected by centrifugation. The precipate was 
was dissolved in THF:MeOH (2 mL) and treated with a slurry of  10 % Pd/C (20 mg) in 
a 25% aqueous solution of  ammonium formate (300 µL) under N2. After 1 h the Pd/C 
was removed by filtering through a plug of Celite. Reverse phase flash 
chromatography (see general reverse phase flash chromatography method) and 
lyophilization, afforded 4 mg of 17 as a beige amorphous solid (17% yield). 1H NMR 
(DMSO- d6, 400 MHz) δ 11.54 (1H, s), 11.37 (1H, s), 9.91 (1H, s), 9.33 (1H, brs), 8.56 
(1H, appt t, J=7.3), 8.21 (1H, appt q, J=5.6), 7.79 (1H, brs), 7.39 (1H, d, J=8.7), 7.28 (1H, 
s), 7.16 (1H, d, J=2.3), 7.03 (1H, s), 6.90 (1H, dd, J= 8.7, 2.3), 4.81-4.72 (1H, m), 4.47-
4.39 (2H, m), 4.16-4.08 (2H, m), 3.99-3.91 (1H, m), 3.78 (3H, s), 3.21-3.12 (2H, m), 3.08-
2.99 (2H, m), 2.76 (6H, s), 1.84-1.75 (2H, m), 1.38 (3H, d, J=7.1). 13C NMR (observed by 
DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 114.8 (CH1), 112.8 (CH1), 104.4 (CH1), 102.6 
(CH1), 101.8 (CH1), 99.4 (CH1), 54.9 (CH3), 54.5 (CH2), 54.3 (CH2), 48.7 (CH1), 47.1 
(CH2), 42.2 (CH3), 42.0 (CH1), 35.2 (CH2), 24.1 (CH2), 17.6 (CH3). HRMS (ES+) 
calculated for C30H36ClN6O5 595.2430 (M+H)+ found 595.2418. 
(18): Rink amide MBHA resin (107 mg, 0.039 mmol, [manufacturer’s resin loading 0.36 
mmol/g]) was prepared for coupling by swelling in CH2Cl2 for 30 min followed by DMF 
for a further 30 min, and treatment with piperidine in DMF (3 mL 40 % 10 min, 3 mL 
20 % 5 min twice). The resin was washed 6 times with DMF (10 mL). Fmoc-Ala-OH (121 
mg, 0.39 mmol), was dissolved in 2 mL of DMF and treated with HBTU (133 mg, 0.39 
mmol), HOBt.H2O (54 mg, 0.39 mmol) and DIPEA (135 µL, 0.78 mmol). After 30 s the 
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solution was added to the resin and shaken for 45 min. The coupling was repeated 
and the resin washed 6 times with DMF (10 mL) prior to Fmoc deprotection with 
piperidine in DMF (3 mL 40 % 10 min, 3 mL 20 % 5 min twice). Following Fmoc 
deprotection the resin was wash a further 6 times with DMF (10 mL).  7 (25 mg, 0.043 
mmol) was dissolved in 2 mL of DMF and treated with HATU (13 mg, 0.043 mmol) and 
DIPEA (16 µL, 0.086 mmol). After 10 s the resulting solution was added to the resin 
and the mixture shaken overnight. The resin was washed 6 times with DMF (10 mL) 
and removal of the Fmoc protection of the indoline nitrogen affected with piperidine 
in DMF (3 mL 40 % 10 min, 3 mL 20 % 5 min twice). Following Fmoc deprotection the 
resin was washed 6 times with DMF (10 mL). 5-methoxyindole-2-carboxylic acid (38 
mg, 0.199 mmol) was dissolved in 2 mL of DMF and treated with HATU (73 mg, 0.191 
mmol) and DIPEA (70 µL, 0.401 mmol). After 10 s the resulting solution was added to 
the resin and the mixture shaken overnight. The resin was washed 6 times with DMF 
(10 mL) and 6 times with CH2Cl2. Cleavage was affected by addition of a solution of 
47% TFA, 47% CH2Cl2, 3% TIPS and 3% H2O (10 mL). After shaking for 2 h the cleavage 
mixture was filtered. The resin was rinsed 3 times with CH2Cl2 (3 mL) and the combined 
filtrates were concentrated to dryness by rotary evaporation under vacuum. The 
crude cleavage product was dissolved in THF:MeOH (2 mL) and treated with a slurry 
of  10 % Pd/C (20mg) in a 25 % aqueous solution of ammonium formate (300 µL) under 
N2. After 1 h the Pd/C was removed by filtering through a plug of Celite. Flash 
chromatography (silica gel, 7 x 1 cm, 10% MeOH in CH2Cl2) and trituration with hexane, 
afforded 6.8 mg of 18 as a beige amorphous solid (34% yield). 1H NMR (DMSO- d6, 400 
MHz) δ 11.54 (1H, s), 11.35 (1H, s), 9.82 (1H, s), 8.46 (1H, d, J=7.6), 7.76 (1H, brs), 7.47 
(1H, brs), 7.38 (1H, d, J= 8.9), 7.27 (1H, d, J= 2.0), 7.15 (1H, d, J=2.3), 7.04 (1H, brs), 
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7.02 (1H, s), 6.89 (1H, dd, J= 8.9, 2.3), 4.80-4.72 (1H, m), 4.51-4.40 (2H, m), 4.16-4.06 
(2H, m), 3.98-3.89 (1H, m), 3.78 (3H, s), 1.35 (3H, d, J=7.1). 13C NMR (observed by 
DEPT-ed-HSQC) (DMSO- d6, 100 MHz) δ 114.7 (CH1), 112.8 (CH1), 104.4 (CH1), 102.3 
(CH1), 101.8 (CH1), 99.3 (CH1), 54.9 (CH3), 54.4 (CH2), 48.0 (CH1), 47.1 (CH2), 41.9 
(CH1) 18.0 (CH3). HRMS (ES+) calculated for C25H25ClN5O5  510.1539 (M+H)+ found 
510.1533. 
Biological Assays. 
Cell culture. 
The HL60 cell line was purchased from ECACC (Porton Down, UK). Cells were cultured 
in RPMI 1640 medium supplemented with 10% foetal calf serum and 2 mM L-
glutamine. HL-60 cells were passaged twice weekly and maintained between 1-9 x 105 
cells/ml at 37 oC and 5% CO2. 
Antiproliferative assay. 
Antiproliferative activity was determined by MTS assay45 using the CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (Promega) and following the manufacturer’s 
instructions. Briefly, HL-60 cells (3 x 104/100 µl) were seeded in 96-well plates and left 
untreated or treated with DMSO (vehicle control), duocarmycins, or doxorubicin 
hydrochloride at 8 concentrations (see below) in triplicate for 72 hr at 37 °C with 5% 
CO2. Following this, MTS assay reagent was added for 4 h and the absorbance 
measured at 490 nm using the Polarstar Optima microplate reader (BMG Labtech). 
IC50 values were calculated using GraphPad Prism Version 5.0 software.   
Concentrations tested:  
Compounds 8, 9, 10, 11, 12, 13, 14, 15, 30, and 31, (500 µM, 250 µM, 100 µM, 10 µM, 
1 µM, 0.1 µM, 0.01 µM, 0.001 µM)  
43 
 
Compounds 16, 17, 18, and doxorubicin (100 µM, 10 µM, 1 µM, 0.1 µM, 0.01 µM, 
0.001 µM, 0.0001 µM, 0.00001 µM) 
DNA alkylation studies: 
DNA cleavage.  The MS1 DNA fragment was prepared as previously described,42 by 
cleaving the parent plasmid with HindIII and SacI and labelling the 3’-end of the HindIII 
site with α-32P[dATP] using Klenow fragment (exo-). 1.5 µL of each compound (diluted 
in 10 mM Tris-HCl pH 7.5, containing 10 mM NaCl) was incubated with 1.5 µL of the 
radiolabelled DNA and incubated overnight at 37 °C. The samples were then mixed 
with an equal volume of formamide containing 10 mM EDTA and ligand specific 
cleavage was induced by heating at 100 °C for 3 minutes. Samples were loaded onto 
8% denaturing polyacrylamide gels containing 8M urea. The dried gel was exposed to 
a phosphorimager screen and analysed using a Typhoon phosphorimager. 
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